Search Results
Oct 19, 2025, 11:42 ET Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with oxaliplatin and capecitabine as first-line
More news about: Akeso, Inc.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Oct. 19, 2025 /PRNewswire/ -- Akeso (9926.HK) announced the groundbreaking results of the registrational Phase III clinical study (AK112-306/HARMONi-6) evaluating ivonescimab (PD-1/VEGF bispecific antibody), a globally first-in-class bispecific antibody developed
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
4 Fayette J, Licitra L, Harrington K, et al. INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer
More news about: Johnson & Johnson
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
- Results from the BL-B01D1-303 (NCT06118333) phase III trial presented in a late-breaking oral presentation at ESMO represents the first data readout for iza-bren from a registration enabling study in China
More news about: SystImmune, Inc.
Oct 19, 2025, 03:00 ET Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
content:https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588336.html
More news about: Multitude Therapeutics, Inc.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
Currently, a Phase III clinical study of sacituzumab tirumotecan as monotherapy and in combination with pembrolizumab in patients with chemotherapy-naïve HR+/HER2- breast cancer is ongoing globally, with a planned enrollment of approximately 1,200 participants. Additionally, another Phase III registrational
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
(i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue
More news about: Astellas Pharma Inc.
Oct 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
On May 30, 2025, Summit issued a press release "announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]" Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Dow Inc. and Certain Officers - DOW
businesses organized into three operating segments: (i) Packaging & Specialty Plastics, (ii) Industrial Intermediates & Infrastructure, and (iii) Performance Materials & Coatings. Historically, Dow has touted its "industry-leading dividend," which is of particular importance
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fortinet, Inc. of Class Action Lawsuit and Upcoming Deadlines - FTNT
upgrade; (ii) suggested customers had "excess [firewall] capacity from [purchasing firewalls in] prior years" and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had "much business impact" as it consisted of only a "small percentage" of the Company's business, as the age
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors;
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in the Securities of Spirit Aviation Holdings, Inc. - FLYYQ
obligations; (ii) Spirit was also at substantial risk of being forced to file for Chapter 11 bankruptcy protection within a mere matter of months; (iii) accordingly, Defendants had overstated enhancements to Spirit's financial condition, liquidity, and overall business and operations, while simultaneously
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Cepton, Inc. and Certain Officers - CPTN
meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito Acquisition; (iii) consequently, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito Acquisition; and
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as
More news about: Pomerantz LLP
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nutex Health Inc. and Certain Officers - NUTX
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: Pomerantz LLP
Oct 18, 2025, 05:03 ET GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
More than half (53.5%) of the new cancers detected by Galleri were stage I or II and more than two-thirds (69.3%) were detected at stages I-III. "Cancer screening saves lives, but we routinely screen for just four or five cancer types in the United States today and approximately
More news about: GRAIL, Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
(FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC): Phase III MIRASOL trial.5-year progression-free survival (PFS) with rucaparib (RUCA) maintenance in patients with newly diagnosed advanced ovarian cancer
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 17:43 ET Cepton, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against CPTN
meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito acquisition; and (iii) as a result, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito acquisition.
More news about: Robbins LLP
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
WAYPOINT Phase III trial, which were presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress and
More news about: Amgen
Oct 17, 2025, 15:36 ET At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More
here, courtesy of Jeff Pinette for STAT Joe Kennedy III Citizens Energy president and former congressman Joe Kennedy III publicly broke with his uncle HHS Secretary Robert F. Kennedy Jr. over "grave concerns" about
More news about: STAT
Oct 17, 2025, 13:23 ET JUDGE JOHN D. BATES HONORED WITH NATION'S HIGHEST JUDICIAL AWARD AT THE SUPREME COURT OF THE UNITED STATES
unsung heroes of our great American judiciary," he would often say. The Devitt Award became the unrivaled crowning recognition bestowed upon an Article III federal judge who has served with tremendous distinction. Every Justice on the Supreme Court has participated in the Devitt Award,
More news about: Dwight D. Opperman Foundation
Oct 17, 2025, 10:03 ET Boost Mobile to Offer the Powerful New iPad Pro with the M5 Chip
fees.ii Results are compared to iPad Pro 13-inch (M4) units with 10-core CPU and 16GB of unified memory. iii Results are compared to iPad Pro 12.9-inch (5th generation) units with 8-core CPU and 16GB of unified memory.iv Apple
More news about: EchoStar Corporation
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
NCT06151574), a Phase III randomized study evaluating HERNEXEOS as a first-line therapy versus standard of care in patients with unresectable, locally advanced or metastatic HER2-mutant
More news about: Boehringer Ingelheim
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
content:https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-promising-interim-phase-iii-results-from-the-ongoing-first-in-human-study-evaluating-its-cd44v9-directed-antibody-drug-conjugate-amt-116-in-heavily-pretreated-egfr-wild-type-non-small-cell-lung--302587390.html
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 09:30 ET Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
domestic business expansion and the implementation of service standardization for the Joint Venture Platform. III. Strategic Value and Shareholder Returns: The Long-term Logic of Capital-Industry Resonance Regarding this
More news about: Visionary Holdings Inc.